EchoPixel introduced what it calls the first-ever intraoperative software to provide naked-eye, touchless interactive 3-D anatomical imaging to support structural heart procedures in the cath lab, operating room (OR) and hybrid OR. The introduction was made at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 meeting, September 25-29, in San Francisco. The company will showcase the turnkey intraoperative solution, which is pending U.S. Food and Drug Administration (FDA) 510(k) clearance, as part of its existing integrated suite of mixed reality software solutions that assist cardiologists and surgeons with visualization of live 3-D medical images during a procedure for more precise catheter and device placement and personalized planning.
September 27, 2019
Videos
Akshay Khandelwal, M.D., director of medical operations at the Henry Ford Heart and Vascular Institute, Detroit, and ...
September 27, 2019
Videos
Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...
September 26, 2019Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC type 2, 3 or 5 bleeding in high-bleed-risk patients who underwent percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT) at 12 months. Brilinta monotherapy (90 mg twice daily) was compared to Brilinta plus low-dose aspirin.
September 26, 2019
Technology | Computed Tomography (CT)
The U.S. Food and Drug Administration (FDA) has cleared three modules of AI-Rad Companion Chest CT, an intelligent software assistant from Siemens Healthineers that brings artificial intelligence (AI) to computed tomography (CT). They include the AI-Rad Companion Engine (K183272), Pulmonary (K183271) and Cardiovascular (K183268) modules. Representing the first intelligent assistant of the new AI-Rad Companion platform, AI-Rad Companion Chest CT helps radiologists interpret images of the thorax (chest) quickly with desired accuracy and precision, and automatically documents these findings as structured reports.
September 26, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to experts when using automated machine learning, according to new research. The study was published in Circulation: Cardiovascular Imaging, an American Heart Association journal.
September 25, 2019Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News | Cath Lab
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized patients with de novo three-vessel and left main coronary artery disease, according to new research. The late-breaking results from the SYNTAX Extended Survival study were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology and published in The Lancet.
September 25, 2019
Technology | Heart Valve Technology
Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Evolut Pro+ transcatheter aortic valve replacement (TAVR) system. The new-generation Medtronic TAVR system builds off the self-expanding, supra-annular Evolut TAVR platform. The Evolut Pro+ TAVR System includes four valve sizes with an external pericardial tissue wrap that provides advanced sealing for the largest indicated patient treatment range and the lowest delivery profile currently on the market, according to Medtronic. The launch comes on the heels of the FDA’s recent indication expansion for the Evolut TAVR platform to treat patients with symptomatic severe aortic stenosis at a low risk of surgical mortality, the final surgical risk category to be approved for TAVR.
September 24, 2019
Videos | Hemodynamic Support Devices
There was a 77 percent increase in survival in cardiogenic shock patients treated using a new protocol in the National ...
September 22, 2019Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News | Congenital Heart
Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart valve and the Amplatzer Piccolo Occluder. Both devices have received CE Mark and are now available in Europe and other countries that recognize CE Mark. The new treatments, already available in the U.S., offer young pediatric patients and their families hope when no other suitable treatment option may exist.
September 20, 2019
News | Leads Implantable Devices
BioTrace Medical Inc. announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place Sept. 25-29, 2019, in San Francisco.
September 20, 2019
News | Drug-Eluting Balloons
Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon (SEB) in the treatment of below-the-knee (BTK) peripheral artery disease.
September 20, 2019Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News | Heart Failure
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to consolidating cardiac care, particularly for patients with heart failure, into a convenient and comprehensive area.
September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The late-breaking results of the ASPREE trial were presented at the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, Aug. 31-Sept. 4 in Paris. France.
September 20, 2019
Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention lengthens survival in patients at high risk of death after ST-segment elevation myocardial infarction (STEMI). The late-breaking results from the DAPA trial were presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress 2019, Aug. 31-Sept. 4 in Paris, France, together with the World Congress of Cardiology.
September 18, 2019© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now